Tin tức & Cập nhật

Although guidelines recommend 12 months of dual antiplatelet therapy (DAPT) following a heart attack, results from the DUAL-ACS* trial appear to show otherwise.

In the phase III BaxHTN trial, the highly selective and potent aldosterone synthase inhibitor baxdrostat efficiently controls blood pressure (BP) when added to background antihypertensive therapy for the treatment of uncontrolled or treatment-resistant hypertension (HTN).